WYNDHAM HOTELS & RESORTS, INC. 8-K

What Happened

• Wyndham Hotels & Resorts (WH) filed an 8-K on May 18, 2026 reporting several governance and personnel items. Nicola Rossi, the Company’s Chief Accounting Officer, will depart effective July 31, 2026 (the parties agreed the final date on May 13, 2026). Christopher Androski, currently Senior Vice President and Controller, will assume the Chief Accounting Officer role as of July 31, 2026. The filing also discloses that President and CEO Geoffrey (Geoff) Ballotti sent a companywide message stating he will undergo treatment for Multiple Myeloma and plans to continue working largely as normal.
• The Company reported final results from its May 14, 2026 Annual Meeting: all nine director nominees were elected, the advisory say-on-pay was approved, Deloitte & Touche LLP was ratified as auditor, and a shareholder proposal on written-consent rights received majority support.

Key Details

• CAO transition: Nicola Rossi departs effective July 31, 2026; Christopher Androski (age 52) will become Chief Accounting Officer; no related-party transactions or special arrangements are reportable under Item 404 for Androski.
• Annual Meeting votes (May 14, 2026): nine directors elected (each received ~63.0–63.9M votes for; broker non-votes: 5,492,330).
• Say-on-pay: Approved on an advisory basis — 54,328,340 For vs. 9,548,555 Against; abstentions 96,113; broker non-votes 5,492,330.
• Auditor ratification: Deloitte & Touche LLP ratified — 69,010,644 For vs. 428,101 Against.
• Shareholder proposal (written-consent rights): Passed — 40,181,784 For vs. 23,709,518 Against; broker non-votes 5,492,330.
• CEO disclosure: Geoff Ballotti announced he will undergo treatment for Multiple Myeloma and intends to continue working; his message is included as Exhibit 99.1 to the filing.

Why It Matters

• Accounting leadership: An internal promotion to CAO (Androski) suggests continuity in financial reporting and controls, which is important for investors monitoring accounting stability and the company’s financial close process.
• Governance and shareholder sentiment: Re-election of the full board and ratification of the auditor indicate governance continuity, while the relatively high opposition to say-on-pay and the passage of the written-consent proposal show meaningful shareholder engagement on compensation and governance matters.
• CEO health: Disclosure that the CEO will undergo cancer treatment is material information for investors because it could affect executive availability and company operations; the CEO’s statement that he plans to continue working provides context, but investors may watch for any further updates on duties or delegation.